F-star’s robust, proprietary clinical pipeline includes three tetravalent mAb2 bispecific programs designed for focused, potent and safe immune activation.
In addition, F-star has an intravenously administered, next generation STING agonist, SB 11285, in clinical trials. Each directed against some of the most promising IO targets in drug development, there is the potential for a life-changing, durable response for patients who have few other options.
FS118: First-in-class LAG-3/PD-L1 mAb2 bispecific antibody
Our most advanced clinical program, FS118, targeting LAG-3 and PD-L1, is currently in a phase 2 Proof of Concept study in acquired resistance head and neck cancer, as well as in a Phase 2 trial in checkpoint naïve non-small cell lung cancer (NSCLC) and diffuse large B cell lymphoma (DLBCL) patients.
FS118 »FS120: First-in-class OX40/CD137 mAb² dual agonist bispecific antibody
FS120 is our dual conditional agonist targeting OX40 and CD137 with the goal of improving outcomes with current standard of care treatments, and is currently in Phase 1 trials.
FS120 »FS222: Potentially best-in-class CD137/PD-L1 mAb² bispecific antibody
FS222 is designed to both stimulate CD137 and inhibit PD-L1, and is in Phase 1 trials currently. We believe FS222 has applicability in PD-L1 low tumors which remains an area with significant unmet need.
FS222 »SB 11285: Second generation STING agonist for intravenous administration
SB 11285 is our second generation STING agonist, currently in a Phase 1 study as both monotherapy and in combination with atezolizumab.
SB 11285 »Proprietary Pipeline
Partnered Programs
